Profil
Marcus Schindler est Chief Scientific Officer et Executive VP-Research chez Novo Nordisk A. Il est titulaire d'un doctorat de l'université de Cambridge.
Dernières actualités sur Marcus Schindler
Anciens postes connus de Marcus Schindler
| Sociétés | Poste | Fin |
|---|---|---|
| NOVO NORDISK A/S | Directeur Technique/Scientifique/R&D | 07/08/2025 |
| INNATE PHARMA | Directeur/Membre du Conseil | 28/05/2021 |
AstraZeneca A/S (Denmark)
AstraZeneca A/S (Denmark) Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical medicines | Corporate Officer/Principal | 01/12/2017 |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Manufactures products for treatment of metabolic diseases | Directeur Technique/Scientifique/R&D | 01/01/2012 |
Formation de Marcus Schindler
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Innate Pharma SA
Innate Pharma SA Pharmaceuticals: MajorHealth Technology Develops therapeutic antibodies that harness the immune system to improve cancer treatment and clinical outcomes | Health Technology |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Manufactures products for treatment of metabolic diseases | Health Technology |
University of Gottingen
University of Gottingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AstraZeneca A/S (Denmark)
AstraZeneca A/S (Denmark) Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical medicines | Health Technology |
















